Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 2,707 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman sold 2,707 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.92, for a total value of $413,954.44. Following the sale, the director now directly owns 517,030 shares of the company’s stock, valued at approximately $79,064,227.60. This trade represents a 0.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Kevin Charles Gorman also recently made the following trade(s):

• On Monday, January 27th, Kevin Charles Gorman sold 146,105 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $149.46, for a total value of $21,836,853.30.

Neurocrine Biosciences Price Performance

Shares of NBIX stock opened at $151.20 on Thursday. The firm has a fifty day moving average of $137.92 and a two-hundred day moving average of $131.51. The firm has a market cap of $15.31 billion, a P/E ratio of 40.54 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98.

Hedge Funds Weigh In On Neurocrine Biosciences

Large investors have recently modified their holdings of the stock. Golden State Wealth Management LLC acquired a new stake in Neurocrine Biosciences during the fourth quarter valued at approximately $25,000. Brooklyn Investment Group increased its holdings in shares of Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after acquiring an additional 115 shares during the last quarter. Blue Trust Inc. raised its position in shares of Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares in the last quarter. R Squared Ltd bought a new position in Neurocrine Biosciences during the fourth quarter worth $61,000. Finally, UMB Bank n.a. boosted its holdings in Neurocrine Biosciences by 211.6% in the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock worth $62,000 after purchasing an additional 309 shares during the period. Institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on NBIX shares. Morgan Stanley raised their price target on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a report on Tuesday. Wedbush reissued an “outperform” rating and issued a $148.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Barclays upped their price target on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday, December 23rd. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Finally, William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $166.85.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.